Weiss Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Weiss Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-795	Closed	-$363K	–	580
2025 Q3	$363K	Buy	+795	New	+$324K	﹤0.01%	516
2024 Q3	–	Sell	-23,800	Closed	-$5.78M	–	600
2024 Q2	$5.78M	Sell	23,800 -876	-4%	-$138K	0.22%	99
2024 Q1	$3.69M	Buy	24,676 +23,484	+1,970%	+$3.92M	0.13%	138
2023 Q4	$228K	Buy	+1,192	New	+$203K	0.01%	292
2022 Q4	–	Sell	-24,450	Closed	-$4.89M	–	543
2022 Q3	$4.89M	Buy	+24,450	New	+$4.66M	0.12%	240
2018 Q4	–	Sell	-2,460	Closed	-$215K	–	456
2018 Q3	$215K	Hold	2,460	–	–	0.02%	145
2018 Q2	$242K	Hold	2,460	–	–	0.02%	132
2018 Q1	$293K	Hold	2,460	–	–	0.02%	143
2017 Q4	$313K	Buy	+2,460	New	+$309K	0.03%	159

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Weiss Asset Management's ALNY Position: Q4 2025 in Review

Weiss Asset Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 795 shares — an estimated $363K sold.

Weiss Asset Management first reported a position in ALNY in Q4 2017 and held it in 9 quarters. The position peaked at $5.78M in Q2 2024. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Weiss Asset Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Weiss Asset Management sold 795 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $363K.
Weiss Asset Management first reported a position in Alnylam Pharmaceuticals in Q4 2017 and held it in 9 quarters.
Weiss Asset Management's Alnylam Pharmaceuticals position peaked at $5.78M in Q2 2024.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Weiss Asset Management's 13F filing for Q4 2025, filed 17 Feb 2026.